Skip to main
LYEL

Lyell Immunopharma (LYEL) Stock Forecast & Price Target

Lyell Immunopharma (LYEL) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lyell Immunopharma has demonstrated strong financial positioning with cash, cash equivalents, and marketable securities totaling $320 million at the end of the quarter, an increase from $297 million in the previous quarter, primarily driven by a private placement. The company’s advancements in its product pipeline, notably the promising data from LYL273 indicating durability in treating complex solid tumors, bolster investor confidence in its technological leadership within the CAR-T market. Additionally, rising probabilities of approval for key candidates such as DLBCL and positive expert feedback further underpin the company's growth potential, reflecting a compelling investment narrative.

Bears say

Lyell Immunopharma's financial outlook is negatively impacted by a decrease in research and development expenditure, which fell to $28.2 million in the third quarter of 2025 from $34.9 million in the second quarter, indicating potential challenges in advancing its product pipeline. Significant risks loom over the company's ability to penetrate the CAR-T market effectively, particularly against existing CD19 CAR-T therapies, as well as concerns regarding the efficacy of its treatments and potential safety events that could alter their risk-benefit profiles. Additionally, the lack of definitive data illustrating long-term durability and manageable toxicity in larger patient populations raises doubts about the viability of LYL273 as a standard-of-care therapy, hindering investor confidence.

Lyell Immunopharma (LYEL) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lyell Immunopharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lyell Immunopharma (LYEL) Forecast

Analysts have given Lyell Immunopharma (LYEL) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Lyell Immunopharma (LYEL) has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lyell Immunopharma (LYEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.